
The study evaluated the efficacy and safety of empagliflozin, a medication used to treat heart failure and type 2 diabetes, in patients with heart failure and preserved left ventricular ejection fraction (LVEF) with and without atrial fibrillation/flutter (AF). The study found that empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure to a similar extent in patients with and without AF. Empagliflozin also reduced total hospitalizations for heart failure and slowed the decline of estimated glomerular filtration rate (eGFR) consistently in patients with and without AF. There was no increase in serious adverse events associated with empagliflozin in either group.
Like
Save
Share